Marijn Dekkers

Dekkers grew up as the youngest of three children of a merchant in the Dutch city of Tilburg. After attending local schools, St. Aloysius (primary school) and St. Odulphus (Lyceum), in 1976 he began studying chemistry at the Radboud University in Nijmegen. Three years later he began studying chemical technology at Eindhoven University of Technology, where he received his master's degree and PhD in chemical engineering.Title of Thesis: The Deformation Behaviour of Glass Beaded-Filled Glassy Polymers

In 1985 Dekkers worked for General Electric (GE) in different research departments located in the US and the Netherlands. In 1988, he became Research Director of the GE range of polymers and subsequently held management positions in various other polymer units.

In 1995, Dekkers joined Allied Signal (later named Honeywell International Inc.) and took over the management of various business units.

In 2000, he became a director at the Boston-based Thermo Electron Corporation,{{Cite web|url=https://www.bizjournals.com/boston/blog/mass-high-tech/2009/09/thermo-fisher-ceo-dekkers-leaves-to-head.html|title=Thermo Fisher CEO Dekkers leaves to head Bayer; Casper appointed CEO|website=www.bizjournals.com|access-date=2018-06-06}} one of the world's leading specialists in the manufacture of laboratory instruments. Within a short time, Dekkers implemented a complete corporate reorganization and became President and CEO in 2002.

In this role, he initiated further extensive restructuring measures, divesting various organizational units and strengthening the company's core business by means of targeted acquisitions, including the purchase in 2006 of the laboratory consumables supplier Fisher Scientific. After the acquisition, the company renamed as Thermo Fisher Scientific, which employed 30,000 people in six business groups.{{Cite news|url=https://www.washingtonpost.com/wp-dyn/content/article/2006/05/08/AR2006050800325_pf.html?noredirect=on|title=Thermo Electron, Fisher Scientific in Deal|newspaper=The Washington Post|access-date=2018-06-06|language=en-US|issn=0190-8286}}

On 1 January 2010 Dekkers was appointed to the board of Bayer AG and on 1 October 2010 he took over as CEO from Werner Wenning.{{cite web | url=http://www.fiercebiotech.com/press-releases/dr-marijn-e-dekkers-be-new-ceo-bayer-october-1-2010 | title=Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 | FierceBiotech| date=15 September 2009}} On 3 June 2014 Bayer AG announced that its Supervisory Board had extended Marijn Dekkers' term as CEO by two years, on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016.{{cite web | url=http://www.fiercepharma.com/story/bayer-ceos-long-goodbye-dekkers-depart-end-2016/2014-06-03 | title=Bayer CEO's long goodbye: Dekkers to depart at end of 2016 | FiercePharma}} He left Bayer on 30 April 2016 and was succeeded by Werner Baumann on 1 May 2016.{{Cite web|url=http://www.bayer.com/en/werner-baumann.aspx|title=Bayer's CEO: Werner Baumann|last=AG|first=Bayer|website=www.bayer.com|access-date=2016-05-02}}

Since April 2016 he was the Chairman of Unilever until 13 November 2019.[https://fd.nl/ondernemen/1324257/geen-nederlander-meer-in-top-tandem-unilever Geen Nederlander meer in top-tandem Unilever ]

In 2017 Dekkers founded Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry (www.novalislifesciences.com).

"Manager of the Year 2014" by German business magazine "Manager Magazin" {{cite web | url=http://www.manager-magazin.de/unternehmen/industrie/marijn-dekkers-ist-manager-des-jahres-a-1004182.html | title=Marijn Dekkers ist "Manager des Jahres"}}

"Business person of the Year 2015" by the "Finanzen Verlag" publishing group and the readers of its publications "€uro am Sonntag", "€uro" and "Börse online" {{cite web | url=http://www.boerse-online.de/nachrichten/aktien/Bayer-Chef-Dekkers-Unternehmer-des-Jahres-Kaldemorgen-Fondsmanager-des-Jahres-1000475038/1 | title=Bayer-Chef Dekkers Unternehmer des Jahres - Kaldemorgen Fondsmanager des Jahres - 03.02.15 - BÖRSE ONLINE}}

"Most Innovative CEO International 2015" by the German industry's "Innovation Award"

{{cite web |url=http://www.innovationspreis.com/ |title=Home |website=innovationspreis.com}}

In 2013 some controversy was sparked during a Financial Times panel discussion with relation to Bayer's kidney and liver cancer drug Nexavar.The original quote causing the debate was "Is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product, quite honestly. It is an expensive product, being an oncology product." – [https://www.cjr.org/the_audit/bloombergs_viral_misquote_1.php Columbia Journalism Review, January 29, 2014], [https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel Videorecording of the panel (19:00 – 19:30)] {{webarchive|url=https://web.archive.org/web/20141111214816/https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel |date=2014-11-11 }}

He spoke at a conference in 2014, saying{{cite web | url=https://www.cjr.org/the_audit/bloombergs_viral_misquote_1.php | title=Bloomberg's viral misquote}}{{cite web | url=http://keionline.org/node/1924 | title=Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar| date=2014-02-07}}{{Quotation|"So now, is this going to have a big effect on our business model? No, because we did not develop this product for the Indian market, let's be honest. I mean, you know, we developed this product for Western patients who can afford this product, quite honestly."{{cite web| url=http://keionline.org/node/1910| title=Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for "western patients who can afford it."| date=2014-01-23| access-date=2014-11-22| archive-url=https://web.archive.org/web/20140124111754/http://keionline.org/node/1910| archive-date=2014-01-24| url-status=dead}}{{cite web|url=https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel |title=Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust - PANEL | Calendar | FT Live |accessdate=2014-11-20 |url-status=dead |archiveurl=https://web.archive.org/web/20141111214816/https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel |archivedate=2014-11-11 }}{{cite web | url=http://timesofindia.indiatimes.com/business/india-business/Pharma-drug-development-only-for-wealthy-countries/articleshow/29456711.cms | title=Pharma drug development only for wealthy countries? - Times of India| website=The Times of India}}}}

Médecins Sans Frontières responded to Dekkers' comment, saying that it {{Quotation|sums up everything that is wrong with the multinational pharmaceutical industry. Bayer is effectively admitting that the drugs they develop are deliberately going to be rationed to the wealthiest patients.http://www.msfaccess.org/content/msf-response-bayer-ceo-statement-medicines-developed-only-western-patients. {{Dead link|date=February 2022}}}} Dekkers replied to this, referring to the decision made by the Indian government, not to protect a patent on Nexavar and the intellectual property of Bayer. He also said: {{Quotation|I regret that what was a quick response from me within the framework of a panel discussion at the recent FT Pharma conference has come across in a different way as it was meant by myself. It could not be more opposite to what I want and we do at Bayer.{{cite web | url=https://www.forbes.com/sites/johnlamattina/2013/12/05/does-pharma-only-develop-drugs-for-those-who-can-pay/?commentId=comment_blogAndPostId/blog/comment/2009-1298-1228 | title=Does Pharma Only Develop Drugs for Those Who Can Pay?| website=Forbes}}}}

Dekkers holds both Dutch and U.S. citizenship.{{Cite web|url=https://www.fiercebiotech.com/biotech/dr-marijn-e-dekkers-to-be-new-ceo-of-bayer-from-october-1-2010|title=Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 {{!}} FierceBiotech|website=www.fiercebiotech.com|date=15 September 2009 |language=en|access-date=2018-06-06}}

• [http://www.europeanceo.com/profiles/2011/01/marijn-dekkers/ Profile at europeanceo.com]

{{Authority control}}

{{DEFAULTSORT:Dekkers, Marijn}}

Category:1957 births

Category:Living people

Category:Radboud University Nijmegen alumni

Category:Eindhoven University of Technology alumni

Category:Dutch chemical engineers

Category:German chief executives

Category:People from Tilburg